New pill for duchenne MD enters Mid-Stage trial in young boys
Disease control
Recruiting now
This study tests an oral drug called SAT-3247 in 51 boys aged 7 to 10 with Duchenne muscular dystrophy who can still walk. The goal is to find the best dose, check safety, and see if it helps muscle strength. Participants take the drug or a placebo for 12 weeks, and all continue …
Phase: PHASE2 • Sponsor: Satellos Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC